b7h3/cd3-targeting t-cell engaging molecule tak-280
Generic: B7H3/CD3-targeting T-cell Engaging Molecule TAK-280
b7h3/cd3-targeting t-cell engaging molecule tak-280: 1 clinical trial tracked.
b7h3/cd3-targeting t-cell engaging molecule tak-280 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about b7h3/cd3-targeting t-cell engaging molecule tak-280, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLTs)
InterventionalRandomizedopen69 enrolledStarted 2022-04Completion 2025-0723 sites · Australia, Canada, Spain, United StatesTakeda